Fexuprazan

Last updated

Fexuprazan
Abeprazan.svg
Clinical data
Trade names Fexuclue
Other namesAbeprazan; DWP14012; DWP-14012
ATC code
Legal status
Legal status
  • Rx in South Korea, Mexico
Identifiers
  • 1-[5-(2,4-Difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C19H17F3N2O3S
Molar mass 410.41 g·mol−1
3D model (JSmol)
  • CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F
  • InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3
  • Key:OUNXGNDVWVPCOL-UHFFFAOYSA-N

Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD). [1] It is a potassium-competitive acid blocker, [2] which is a class of drugs suppressing gastric acids. [3] [4]

Fexuprazan is approved for clinical use in South Korea, [4] [5] Mexico, [6] Philippines, [7] Chile, [8] and Ecuador. [9]

References

  1. ↑ Ramani A, Merchant A, Cash BD (August 2023). "Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease". European Journal of Clinical Pharmacology. 79 (8): 1023–1029. doi:10.1007/s00228-023-03521-4. PMID   37344679. S2CID   259222741.
  2. ↑ Kim GH, Choi MG, Kim JI, Lee ST, Chun HJ, Lee KL, et al. (November 2023). "Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis". Gut and Liver. 17 (6): 884–893. doi:10.5009/gnl220457. PMC   10651377 . PMID   36789577.{{cite journal}}: CS1 maint: overridden setting (link)
  3. ↑ Jeong YS, Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, et al. (May 2021). "Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans". Pharmaceutics. 13 (6): 813. doi: 10.3390/pharmaceutics13060813 . PMC   8229463 . PMID   34072547.
  4. 1 2 Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, Lee KR (June 2022). "Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans". Pharmaceuticals. 15 (6): 709. doi: 10.3390/ph15060709 . PMC   9230547 . PMID   35745628.
  5. ↑ "펙수클루정40밀리그램(펙수프라잔염산염)" [Fexuclue tablets 40 mg (fexuprazan hydrochloride)]. nedrug.mfds.go.kr (in Korean).
  6. ↑ "Daewoong Pharma's GER drug gets product OK from Mexico". Korea Economic Daily. 19 October 2023.
  7. ↑ Park IH. "Daewoong launches GERD treatment Fexuclu in Philippines". KED Global. Retrieved 4 April 2025.
  8. ↑ Lee JH (14 March 2023). "Daewoong wins approval for GERD treatment Fexuclu in Chile". KED Global. Retrieved 4 April 2025.
  9. ↑ Kim JE. "Daewoong receives approval for its GERD drug Fexuclue in Ecuador". KED Global. Retrieved 4 April 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.